Factors related to weight gain in patients with schizophrenia treated with serotonin-dopamine antagonists

被引：0
|
作者：
Jang, WSJ
Kim, SKK
Choi, KSC
Park, DYP
Han, WSH
Hong, KSH
Lee, DSL
机构：
[1] Samsung Med Ctr, Dept Psychiat, Seoul, South Korea
[2] St Andrew Neuropsychiat Hosp, Dept Psychiat, Ichon, South Korea
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2004年 / 14卷
关键词：
D O I：
10.1016/S0924-977X(04)80232-3
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S237 / S237
页数：1
相关论文
共 50 条
  • [31] SYSTEMS BIOLOGY APPROACH TO EVALUATE GENETIC FACTORS OF ANTIPSYCHOTIC INDUCED WEIGHT GAIN IN PATIENTS WITH SCHIZOPHRENIA
    Hauschild, Anne-Christin
    Maciukiewicz, Malgorzata
    Tiwari, Arun
    Zai, Clement
    Liebermann, Jeffrey A.
    Meltzer, Herbert
    Kennedy, James L.
    Mueller, Daniel
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : 1122 - 1122
  • [32] The antidepressant-like effect and proposed mechanism of action of TPN672MA, a novel serotonin-dopamine receptor modulator for the treatment of schizophrenia
    Cheng, Jiaxin
    Wu, Chunhui
    Wang, Yu
    Wang, Zhen
    He, Yang
    Shen, Jingshan
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2024, 242
  • [33] Metabolic syndrome and related factors treated with antipsychotics monotherapy and polypharmacy in patients with schizophrenia
    Oncu, Fatih
    Acuner, Tufan T.
    Atlar, Fatmahan
    Turkcan, Solmaz
    Yesilbursa, Dogan
    Uygur, Niyazi
    KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, 2009, 19 : S292 - S295
  • [34] Amantadine for weight gain in olanzapine-treated patients
    Debert, W
    Trzaskoma, Q
    Carlson, C
    Bymaster, F
    Winokur, A
    Floris, M
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S235 - S235
  • [35] Amantadine for weight gain in olanzapine-treated patients
    Deberdt, W
    Trzaskoma, Q
    Carlson, C
    Bymaster, F
    Winokur, A
    Floris, M
    SCHIZOPHRENIA RESEARCH, 2004, 67 (01) : 182 - 182
  • [36] Medication-induced weight gain and dyslipidemia in patients with schizophrenia
    Fenton, Wayne S.
    Chavez, Mark R.
    AMERICAN JOURNAL OF PSYCHIATRY, 2006, 163 (10) : 1697 - 1704
  • [37] Predictive Role of Serotonin Receptor (5HTR2A) and Dopamine Receptor (DRD2) gene polymorphisms in risperidone-induced weight gain and hyperprolactinemia in patients with schizophrenia
    Alladi Charanraj Goud
    Ravi Philip Rajkumar
    Deepak Gopal Shewade
    Luxitaa Goenka
    Suresh Kumar Srinivasamurthy
    European Journal of Clinical Pharmacology, 2025, 81 (6) : 899 - 905
  • [38] The complexity of using D2-dopamine antagonists in the treatment of patients with schizophrenia
    Wiesel, F. -A.
    Bjerkenstedt, L.
    Edman, G.
    Flyckt, L.
    Venizelos, N.
    EUROPEAN PSYCHIATRY, 2007, 22 : S5 - S6
  • [39] INSIG2 polymorphism and weight gain, dyslipidemia and serum adiponectin in Finnish patients with schizophrenia treated with clozapine
    Koskinen, Suvi
    Kampman, Olli
    Solismaa, Anssi
    Lyytikainen, Leo-Pekka
    Seppala, Niko
    Viikki, Merja
    Hamalainen, Mari
    Moilanen, Eeva
    Mononen, Nina
    Lehtimaki, Terho
    Leinonen, Esa
    PHARMACOGENOMICS, 2016, 17 (18) : 1987 - 1997
  • [40] The Serotonin-Dopamine Relationship on the Aggression-Suicidal Risk Axis in Patients with Major Depression Disorder: Describing Some Social Implications
    Prepelita, Raluca
    Cristofor, Ana-Caterina
    Dobrin, Romeo
    Trus, Constantin
    Ciobica, Alin
    Chirita, Roxana
    REVISTA DE CERCETARE SI INTERVENTIE SOCIALA, 2019, 65 : 111 - 130
12345